ArchPoint Investors’s PTC Therapeutics PTCT Stock Holding History

ArchPoint Investors’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-2,000	Closed	-$75K	–	135
2019 Q1	$75K	Buy	+2,000	New	+$67.2K	0.02%	101

Other funds holding PTCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

ArchPoint Investors's PTCT Position: Q2 2019 in Review

ArchPoint Investors sold out of PTC Therapeutics (PTCT) in Q2 2019, closing a stake of 2,000 shares — an estimated $75K sold.

ArchPoint Investors first reported a position in PTCT in Q1 2019 and held it in 1 quarter. The position peaked at $75K in Q1 2019. 176 funds tracked by Wall St. Rank hold PTCT as of Q2 2019.

ArchPoint Investors reported no remaining PTC Therapeutics position as of Q2 2019 after selling out during the quarter.
ArchPoint Investors sold 2,000 PTC Therapeutics shares in Q2 2019, an estimated $75K.
ArchPoint Investors first reported a position in PTC Therapeutics in Q1 2019 and held it in 1 quarter.
ArchPoint Investors's PTC Therapeutics position peaked at $75K in Q1 2019.
176 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2019.

Based on ArchPoint Investors's 13F filing for Q2 2019, filed 26 Jul 2019.